CVM
CEL-SCIยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CVM
Cel-Sci Corporation
A company that develops immunotherapeutic agents and peptides to treat cancer and bacterial and viral infections
Biological Technology
03/22/1983
06/05/1997
American Stock Exchange
44
09-30
Common stock
8229 Boone Blvd.
, Suite 802
, Vienna
, VA 22182
--
CEL-SCI Corporation was founded on March 22, 1983 and registered in Colorado, focusing on the development of modern marketing, biological sciences and ultimately product sales. The company aims to use the immune system and the body's natural resistance system to research and improve the treatment of cancer and other diseases. The investigational treatment it leads is Multikine, which is currently in the critical third clinical research phase. CEL-SCI is also experimenting with an immunotherapy to see if it has a cure for patients infected with HINI, and it is also using its advanced technology platform to test whether the therapy can cure rheumatoid arthritis. The investigative immunotherapy, LEAPS-H1N1-DC, incorporates invariance of HINI, avian influenza and Spanish influenza, and scientists are concerned that new and more pathogenic viruses will emerge due to the combination of these types of influenza.
Company Financials
EPS
CVM has released its 2025 Q3 earnings. EPS was reported at -1.36, versus the expected 0, missing expectations. The chart below visualizes how CVM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
